GENE ONLINE|News &
Opinion
Blog

2023-03-15| Special

Novo Nordisk Announces Major Insulin Price Cut by Up to 75%, Following in the Footsteps of Eli Lilly

by Richard Chau
Share To
Danish drugmaker Novo Nordisk recently announced a reduction in the list price of several insulin drugs in the United States by up to 75%, making it the latest major pharmaceutical company to slash the insulin price amid pressure to curb the treatment costs for diabetics in the country. 

The price change, which will take effect on January 1, 2024, follows a path set earlier this month by Eli Lilly, one of the major rivals of Novo Nordisk in the insulin market of the United States. It involves the company’s pre-filled pens (FlexPen) as well as vials of long- and short-acting insulins, including Levemir, Novolin, NovoLog and NovoLog Mix70/30. 

The list prices for Levemir and Novolin vials and FlexPens will be reduced by 65%, while NovoLog and NovoLog Mix 70/30 will become 75% cheaper. The list prices of unbranded insulin products will also be reduced to match lowered prices of respective branded insulin products.

GO Prime with only $1.49 now

LATEST
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Scroll to Top